Moderna's (MRNA) Market Perform Rating Reiterated at William Blair

Moderna (NASDAQ:MRNA - Get Free Report)'s stock had its "market perform" rating reaffirmed by analysts at William Blair in a research note issued on Monday,RTT News reports.

Several other research analysts also recently commented on the company. Morgan Stanley decreased their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. UBS Group decreased their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Citigroup started coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Royal Bank of Canada decreased their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Finally, Bank of America lowered their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Moderna has a consensus rating of "Hold" and an average target price of $53.58.

Moderna Stock Down 1.9%

MRNA traded down $0.54 during trading on Monday, hitting $27.27. The company's stock had a trading volume of 7,730,249 shares, compared to its average volume of 8,239,533. The business's 50 day simple moving average is $26.23 and its 200-day simple moving average is $33.71. The firm has a market cap of $10.55 billion, a PE ratio of -2.94 and a beta of 1.86. Moderna has a one year low of $23.15 and a one year high of $158.82.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping the consensus estimate of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna's revenue was down 35.3% on a year-over-year basis. During the same period in the prior year, the business posted ($3.07) EPS. Equities research analysts expect that Moderna will post -9.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Moderna

Several large investors have recently bought and sold shares of MRNA. FMR LLC lifted its position in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after purchasing an additional 1,282,469 shares during the last quarter. Theleme Partners LLP lifted its holdings in shares of Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after acquiring an additional 72,028 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after acquiring an additional 171,774 shares during the last quarter. Invesco Ltd. grew its position in Moderna by 17.5% in the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock worth $166,801,000 after acquiring an additional 877,162 shares in the last quarter. Finally, Norges Bank bought a new stake in Moderna during the fourth quarter worth approximately $163,833,000. Institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.